8,685 total views, 4 views today
Promulgation Date: 2020-2-26 Title: Notice on Adjusting the Usage and Dosage of Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia Document Number:国卫办医函〔2020〕165号 Expiration date: Promulgating Entities:General Office of the National Health Commission, General Office of the State Administration of Traditional Chinese Medicine Source of text: http://www.nhc.gov.cn/yzygj/s7653p/202002/0293d017621941f6b2a4890035243730.shtml DO NOT TAKE ANY MEDICATION WITHOUT CONSULTING A PHYSICIAN DO NOT TAKE ANY MEDICATION WITHOUT CONSULTING A PHYSICIAN DO NOT TAKE ANY MEDICATION WITHOUT CONSULTING A PHYSICIAN
To the health commissions and bureaus of traditional Chinese medicine for each province, autonomous region, directly-governed municipality, and the Xinjiang Production and Construction Corps:
The "Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition)" allows for chloroquine phosphate and other drugs to be clinically tested as anti-viral medication, and recommends usage and dosage according to the clinical trials of the drug. Recently, the clinical trial data on chloroquine phosphate has become more abundant, and in order to ensure that clinical use of the drug is safer and more efficient, research shows that the usage and dosage of chloroquine phosphate for the treatment of novel coronavirus pneumonia are to be adjusted as follows:
I. Applicable Population, Usage, and Dosage
Chloroquine phosphate is suitable for the treatment of novel coronavirus pneumonia in adults aged 18 to 65 years old. For those weighing more than 50 kg, the course of treatment is 7 days with 500mg given twice a day; for those weighing 50 kg or less, the course of treatment is 7 days with 500 mg given twice a day on the 1st and 2nd days, then 500 mg given once a day for the 3rd to 7th day.
II. Contraindications and Relative Contraindications
Pregnancy; allergy to 4-aminoquinolines; cardiac arrhythmia (such as heart block); chronic heart disease; chronic liver or kidney diseases that reach terminal stages; a history of retinal disease, hearing loss or deafness; history of mental illness; skin diseases (include rash, dermatitis, and psoriasis); glucose-6-phosphate dehydrogenase deficiency; concurrent usage of the following for pre-existing conditions: digoxin and derivatives, phenylbutazone, heparin, penicillamine, amiodarone, bepridil, domperidone, droperidol, haloperidol, azithromycin, astemizole, erythromycin, clarithromycin, posaconazole, methadone, procainamide, hydrochlorothiazide, sparfloxacin, levofloxacin, moxifloxacin, cisapride, indapamide, chlorpromazine, streptomycin, penicillamine, ammonium chloride, ondansetron, apomorphine, octreotide, MAO inhibitors, and triamcinolone.
III. Matters for attention
In using chloroquine phosphate to treat patients with novel coronavirus pneumonia, electrocardiogram examination must be normal prior to medication, and the simultaneous use of quinolones, macrolide antibiotics and other drugs that may cause QT interval prolongation is prohibited At the same time, ensure the patient has stable electrolyte levels (potassium, sodium, chloride), normal blood sugar, and normal liver and kidney functions. Pay attention to potential drug interactions. Using 3 or more antiviral drugs (including chloroquine phosphate) is not recommended. Closely monitor adverse drug reactions and discontinue the drug if intolerable toxicity is present. Strictly follow the requirement of "Measure for Reporting and Monitoring of Adverse Drug Reactions" to carry out the monitoring and reporting of adverse drug reactions and ensure drug safety.